Clinical Trials Browser

Completed × Prostatic Neoplasms × durvalumab × Clear all

NCT02788773 2025-05-15

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

52 enrolled 12 charts

Prostatic Neoplasms

NCT03518606 2025-01-15

MOVIE

Phase 1/2 Completed

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03204812 2024-10-15

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

31 enrolled 12 charts

Prostatic Neoplasms

NCT04089553 2024-04-16

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Phase 2 Completed

59 enrolled 19 charts

Prostatic Neoplasms

NCT04495179 2023-08-09

AARDVARC

Phase 2 Completed

30 enrolled 22 charts

Prostatic Neoplasms

NCT02740985 2023-05-26

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Phase 1 Completed

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Colorectal Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous